Government-Owned Inventions; Availability for Licensing, 42352-42353 [05-14499]

Download as PDF 42352 Federal Register / Vol. 70, No. 140 / Friday, July 22, 2005 / Notices ligament (PDL) and the adjacent bone and cementum. The effects of Periodontal Disease range from simple gum inflammation to, in extreme cases, tooth loss. The NIH announces a new technology wherein stem cells from the PDL have been isolated from adult human PDL. Postnatal Stem Cells and Uses Thereof These cells are capable of forming Drs. Songtao Shi and Pamela Robey cementum and PDL in (NIDCR) immunocompromised mice. In cell PCT Application No. PCT/US03/12276 culture, PDL stem cells differentiate into filed 19 Apr 2003 (HHS Reference No. collagen fiber forming cells (fibroblasts), E–018–2003/0–PCT–01), which cementoblasts, and adipocytes. It is published as WO 2004/094588 A2 on anticipated that these PDL stem cells 04 Nov 2004. will be useful for periodontal tissue Licensing Contact: Marlene Shinn-Astor; regeneration to treat periodontal (301) 435–4426; disease. shinnm@mail.nih.gov. Dated: July 15, 2005. Many individuals with ongoing and Steven M. Ferguson, severe dental problems are faced with Director, Division of Technology Development the prospect of permanent tooth loss. and Transfer, Office of Technology Transfer, Examples of such dental problems National Institutes of Health. include: Dentinal degradation due to [FR Doc. 05–14498 Filed 7–21–05; 8:45 am] chronic dental disease (caries or BILLING CODE 4140–01–P periodontal); mouth injury; or through surgical removal, such as with tumors associated with the jaw. For many, a DEPARTMENT OF HEALTH AND technology that offers a possible HUMAN SERVICES alternative to artificial dentures by National Institutes of Health designing and transplanting a set of living teeth fashioned from an Government-Owned Inventions; individual’s own pulp cells would Availability for Licensing greatly improve their quality of life. The NIH announces a new technology AGENCY: National Institutes of Health, wherein human postnatal deciduous Public Health Service, DHHS. dental pulp stem cells commonly ACTION: Notice. known as ‘‘baby teeth’’, are used to create dentin and have been shown to SUMMARY: The inventions listed below differentiate into cells of specialized are owned by an agency of the U.S. function such as neural cells, Government and are available for adipocytes, and odontoblasts. It is licensing in the U.S. in accordance with believed that these cells could be 35 U.S.C. 207 to achieve expeditious manipulated to repair damaged teeth, commercialization of results of induce the regeneration of bone, and federally-funded research and treat neural injury or disease. development. Foreign patent This research is described, in part, in applications are filed on selected Miura et al., ‘‘SHED: Stem cells from inventions to extend market coverage human exfoliated deciduous teeth,’’ for companies and may also be available Proc. Natl. Acad. Sci. USA, vol. 100 (no. for licensing. 10; May 13, 2003) pp. 5807–5812. ADDRESSES: Licensing information and copies of the U.S. patent applications Multipotent Postnatal Stem Cells From Human Periodontal Ligament and Uses listed below may be obtained by writing to the indicated licensing contact at the Thereof Office of Technology Transfer, National Dr. Songtao Shi et al. (NIDCR) Institutes of Health, 6011 Executive PCT Application No. PCT/US04/39248 Boulevard, Suite 325, Rockville, filed 22 Nov 2004 (HHS Reference No. Maryland 20852–3804; telephone: (301) E–033–2004/0–PCT–02), claiming 496–7057; fax: (301) 402–0220. A signed priority to 20 Nov 2003. Confidential Disclosure Agreement will Licensing Contact: Marlene Shinnbe required to receive copies of the Astor; (301) 435–4426; patent applications. shinnm@mail.nih.gov. Cloning of a Genomic DNA Fragment It is estimated that over 40 percent of Containing the Guinea Pig CXCR1 the adult population in the United Gene, a Specific Receptor for Guinea States has periodontal disease in one Pig Interleukin-8 form or another. Periodontal Disease is a chronic infection of the periodontal Teizo Yoshimura (NCI) pulp tissue that has the ability to grow and proliferate in vitro. These (dental pulp) stem cells can be induced under defined culture conditions to form calcified nodules in vitro and have been shown to differentiate into a dentin/ pulp like structure in vivo. VerDate jul<14>2003 19:28 Jul 21, 2005 Jkt 205001 PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 HHS Reference No. E–242–2005/0— Research Tool Licensing Contact: Jesse S. Kindra; (301) 435–5559; kindraj@mail.nih.gov. The present invention relates to cloning of a genomic DNA fragment containing the guinea pig CXCR1 gene, a specific receptor for guinea pig interleukin-8 (IL–8). More specifically, the IL–8–CXCR1 axis is a major chemokine-chemokine receptor system that regulates the recruitment of neutrophils into sites of inflammation. In this invention, the inventors cloned a genomic DNA clone containing the gene for guinea pig IL– 8 receptor CXCR1. Mice and rats are the most commonly used small animals to examine the efficacy of drugs developed for human use. However, neither IL–8 nor CXCR1, a specific receptor for IL– 8, is present in these animals, making it impossible to use them as a model to test the effects or IL–8 or CXCR1 antagonists. Identification of CXCR1, along with IL–8, in the guinea pig may enable evaluation of the in vivo effects of the antagonists. In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors. Anti-CD30 Antibodies That Bind To Intact CD30 but not to Soluble CD30 Satoshi Nagata and Ira Pastan (NCI) U.S. Provisional Application No. 60/ 681,929 filed 16 May 2005 (HHS Reference No. E–208–2005/0–US–01), Licensing Contact: Jesse S. Kindra; (301) 435–5559; kindraj@mail.nih.gov. Human CD30 is a promising target for cancer immunotherapy since CD30 is highly expressed in Hodgkin’s disease and anaplastic large-cell lymphoma. However, soluble CD30, the extracellular domain of CD30 that is shed from the cells, can reduce the effects of CD30-targeting agents by competitive binding. This invention is the first successful attempt of producing CD30-targeting agents without the disadvantage of the reducing effects caused by soluble CD30. More specifically, two (2) epitopes on membrane-associated CD30 have been identified that are missing on soluble CD30. These epitopes are potentially superior targets for immunotherapy since targeting the epitopes should be free from the competitive effects of soluble CD30. Accordingly, the antibodies described in this invention may be used as targeting reagents for cancer therapy. In addition to licensing, the technology is available for further E:\FR\FM\22JYN1.SGM 22JYN1 Federal Register / Vol. 70, No. 140 / Friday, July 22, 2005 / Notices development through collaborative research opportunities with the inventors. Isolation, Cloning and Characterization of New Adeno-Associated Virus (AAV) Serotypes Michael Schmidt et al. (NIDCR) U.S. Provisional Application No. 60/ 676,604 filed 29 April 2005 (HHS Reference No. E–179–2005/0–US–01) Licensing Contact: Jesse S. Kindra; (301) 435–5559; kindraj@mail.nih.gov. This invention relates to new adenoassociated viruses (AAV), vectors and particles derived therefrom and also provides methods for delivering specific nucleic acids to cells using the AAV vectors and particles. Vectors based on these new AAV serotypes may have a different host range and different immunological properties, thus allowing for more efficient transduction in certain cell types. In addition, characterization of these new serotypes will aid in identifying viral elements required for tissue tropism. More specifically, in order to identify and characterize novel AAV isolates for development as gene therapy vectors, the inventors screened approximately one hundred (100) viral stocks. The inventors cloned and sequenced the genomes of AAVs found in twelve (12) simian adenovirus isolates and determined that the AAVs were novel. Ten (10) of these isolates had high similarity to AAV1 and AAV6 (>98%). Despite the high homology to AAV6, these novel AAVs demonstrated distinct cell tropisms and reactivity towards a panel of lectins, suggesting that they may use a distinct entry pathway. Therefore, these novel AAVs may be useful for gene therapy applications. In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors. Anti-Mesothelin Antibodies Useful for Immunological Assays Ira H. Pastan and Masanori Onda (NCI) U.S. Provisional Application No. 60/ 681,104 filed 12 May 2005 (HHS Reference No. E–015–2005/0–US–01), Licensing Contact: Jesse S. Kindra; (301) 435–5559; kindraj@mail.nih.gov. This invention provides antibodies that have a surprisingly good combination of affinity for mesothelin and ability to be used in immunological assays for detecting the presence of mesothelin in biological samples. The invention further relates to methods of using antibodies and kits comprising them. The antibodies can also be used to target toxins and other agents to cells VerDate jul<14>2003 19:28 Jul 21, 2005 Jkt 205001 expressing mesothelin, and can be used in methods and medicaments for inhibiting the growth of such cells. In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors. Methods for the Identification and Use of Compounds Suitable for the Treatment of Drug Resistant Cells Gergely Szakacs et al. (NCI) HHS Reference No. E–075–2004/2– PCT–01 filed 17 Jun 2005 Licensing Contact: Jesse S. Kindra; (301) 435–5559; kindraj@mail.nih.gov. There is an important need to overcome cancer multiple drug resistance (MDR). ATP-binding cassette (ABC) transporters are a family of transporter proteins that contribute to drug resistance via ATP-dependent drug efflux pumps. Accordingly, based on the expression profile of 48 ABC transporters in sixty (60) cell lines, the present invention provides a method to identify (1) drugs that retain action in cells expressing MDR proteins, (2) compounds that reduce MDR by interfering with the efflux pumps. In addition, the invention describes a method to identify compounds whose antiproliferative effect is potentiated by the ABCB1/MDR1 transporter. These compounds might avoid the welldocumented side-effects observed in clinical trials of ‘‘classical’’ MDR1 inhibitors and may serve as leads for development of novel anti-cancer agents to treat resistant disease. Dated: July 15, 2005. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 05–14499 Filed 7–21–05; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Human Genome Research Institute; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Council for Human Genome Research. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign PO 00000 Frm 00055 Fmt 4703 Sfmt 4703 42353 language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Advisory Council for Human Genome Research. Date: September 11–13, 2005. Closed: September 11, 2005, 7 p.m. and 10 p.m. Agenda: To review and evaluate grant applications and/or proposals. Place: Double Tree Rockville, 1750 Rockville Pike, Rockville, MD 20852. Open: September 12, 2005, 8:30 a.m. to 12 p.m. Agenda: To discuss matters of program relevance. Place: National Institutes of Health, 5635 Fishers Lane, Bethesda, MD 20892. Closed: September 12, 2005, 1 p.m. to 5 p.m. on September 13, 2005. Agenda: To review and evaluate grant applications and/or proposals. Place: National Institutes of Health, 5635 Fishers Lane, Bethesda, MD 20892. Contact Person: Mark S. Guyer, PhD, Director of Extramural Research, National Human Genome Research Institute, 5635 Fishers Lane, Suite 4076, MSC 9305, Bethesda, MD 20892, 301–496–7531, guyerm@mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Information is also available on the Institute’s/Center’s home page: https:// www.genome.gov/11509849, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS) Dated: July 15, 2005. Anthony M. Coelho, Jr., Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 05–14492 Filed 7–21–05; 8:45 am] BILLING CODE 4140–01–M E:\FR\FM\22JYN1.SGM 22JYN1

Agencies

[Federal Register Volume 70, Number 140 (Friday, July 22, 2005)]
[Notices]
[Pages 42352-42353]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-14499]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: (301) 496-7057; fax: (301) 402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Cloning of a Genomic DNA Fragment Containing the Guinea Pig CXCR1 Gene, 
a Specific Receptor for Guinea Pig Interleukin-8

Teizo Yoshimura (NCI)
HHS Reference No. E-242-2005/0--Research Tool
Licensing Contact: Jesse S. Kindra; (301) 435-5559; 
kindraj@mail.nih.gov.

    The present invention relates to cloning of a genomic DNA fragment 
containing the guinea pig CXCR1 gene, a specific receptor for guinea 
pig interleukin-8 (IL-8).
    More specifically, the IL-8-CXCR1 axis is a major chemokine-
chemokine receptor system that regulates the recruitment of neutrophils 
into sites of inflammation. In this invention, the inventors cloned a 
genomic DNA clone containing the gene for guinea pig IL-8 receptor 
CXCR1. Mice and rats are the most commonly used small animals to 
examine the efficacy of drugs developed for human use. However, neither 
IL-8 nor CXCR1, a specific receptor for IL-8, is present in these 
animals, making it impossible to use them as a model to test the 
effects or IL-8 or CXCR1 antagonists. Identification of CXCR1, along 
with IL-8, in the guinea pig may enable evaluation of the in vivo 
effects of the antagonists.
    In addition to licensing, the technology is available for further 
development through collaborative research opportunities with the 
inventors.

Anti-CD30 Antibodies That Bind To Intact CD30 but not to Soluble CD30

Satoshi Nagata and Ira Pastan (NCI)
U.S. Provisional Application No. 60/681,929 filed 16 May 2005 (HHS 
Reference No. E-208-2005/0-US-01),
Licensing Contact: Jesse S. Kindra; (301) 435-5559; 
kindraj@mail.nih.gov.

    Human CD30 is a promising target for cancer immunotherapy since 
CD30 is highly expressed in Hodgkin's disease and anaplastic large-cell 
lymphoma. However, soluble CD30, the extracellular domain of CD30 that 
is shed from the cells, can reduce the effects of CD30-targeting agents 
by competitive binding.
    This invention is the first successful attempt of producing CD30-
targeting agents without the disadvantage of the reducing effects 
caused by soluble CD30. More specifically, two (2) epitopes on 
membrane-associated CD30 have been identified that are missing on 
soluble CD30. These epitopes are potentially superior targets for 
immunotherapy since targeting the epitopes should be free from the 
competitive effects of soluble CD30. Accordingly, the antibodies 
described in this invention may be used as targeting reagents for 
cancer therapy.
    In addition to licensing, the technology is available for further

[[Page 42353]]

development through collaborative research opportunities with the 
inventors.

Isolation, Cloning and Characterization of New Adeno-Associated Virus 
(AAV) Serotypes

Michael Schmidt et al. (NIDCR)
U.S. Provisional Application No. 60/676,604 filed 29 April 2005 (HHS 
Reference No. E-179-2005/0-US-01)
Licensing Contact: Jesse S. Kindra; (301) 435-5559; 
kindraj@mail.nih.gov.
    This invention relates to new adeno-associated viruses (AAV), 
vectors and particles derived therefrom and also provides methods for 
delivering specific nucleic acids to cells using the AAV vectors and 
particles. Vectors based on these new AAV serotypes may have a 
different host range and different immunological properties, thus 
allowing for more efficient transduction in certain cell types. In 
addition, characterization of these new serotypes will aid in 
identifying viral elements required for tissue tropism.
    More specifically, in order to identify and characterize novel AAV 
isolates for development as gene therapy vectors, the inventors 
screened approximately one hundred (100) viral stocks. The inventors 
cloned and sequenced the genomes of AAVs found in twelve (12) simian 
adenovirus isolates and determined that the AAVs were novel. Ten (10) 
of these isolates had high similarity to AAV1 and AAV6 (>98%). Despite 
the high homology to AAV6, these novel AAVs demonstrated distinct cell 
tropisms and reactivity towards a panel of lectins, suggesting that 
they may use a distinct entry pathway. Therefore, these novel AAVs may 
be useful for gene therapy applications.
    In addition to licensing, the technology is available for further 
development through collaborative research opportunities with the 
inventors.

Anti-Mesothelin Antibodies Useful for Immunological Assays

Ira H. Pastan and Masanori Onda (NCI)
U.S. Provisional Application No. 60/681,104 filed 12 May 2005 (HHS 
Reference No. E-015-2005/0-US-01),
Licensing Contact: Jesse S. Kindra; (301) 435-5559; 
kindraj@mail.nih.gov.

    This invention provides antibodies that have a surprisingly good 
combination of affinity for mesothelin and ability to be used in 
immunological assays for detecting the presence of mesothelin in 
biological samples. The invention further relates to methods of using 
antibodies and kits comprising them. The antibodies can also be used to 
target toxins and other agents to cells expressing mesothelin, and can 
be used in methods and medicaments for inhibiting the growth of such 
cells.
    In addition to licensing, the technology is available for further 
development through collaborative research opportunities with the 
inventors.

Methods for the Identification and Use of Compounds Suitable for the 
Treatment of Drug Resistant Cells

Gergely Szakacs et al. (NCI)
HHS Reference No. E-075-2004/2-PCT-01 filed 17 Jun 2005
Licensing Contact: Jesse S. Kindra; (301) 435-5559; 
kindraj@mail.nih.gov.

    There is an important need to overcome cancer multiple drug 
resistance (MDR). ATP-binding cassette (ABC) transporters are a family 
of transporter proteins that contribute to drug resistance via ATP-
dependent drug efflux pumps. Accordingly, based on the expression 
profile of 48 ABC transporters in sixty (60) cell lines, the present 
invention provides a method to identify (1) drugs that retain action in 
cells expressing MDR proteins, (2) compounds that reduce MDR by 
interfering with the efflux pumps. In addition, the invention describes 
a method to identify compounds whose antiproliferative effect is 
potentiated by the ABCB1/MDR1 transporter. These compounds might avoid 
the well-documented side-effects observed in clinical trials of 
``classical'' MDR1 inhibitors and may serve as leads for development of 
novel anti-cancer agents to treat resistant disease.

    Dated: July 15, 2005.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 05-14499 Filed 7-21-05; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.